Methylmalonic acidemia with recurrent hemophagocytic lymphohistiocytosis: a case report and review of the literature.

Sooyoung Lee, Yasunari Sakai, Masataka Ishimura, Kei Murayama, Fumiya Yamashita, Satoshi Akamine, Pin Fee Chong, Kenichi Maeda, Saori Kawakami, Ryutaro Kira

Journal: BMC pediatrics 2025;25(1):259

PMID: 40165196

Abstract

BACKGROUND

Methylmalonic acidemia is a rare autosomal recessive disorder of propionate catabolism characterized by the accumulation of propionic acid and methylmalonic acid caused by methylmalonyl-CoA mutase deficiency. Clinical presentations range from acute deterioration in the neonatal period to later onset with a heterogeneous clinical course. Metabolite accumulation results in systemic involvement, affecting the nervous, gastrointestinal, and renal system functions and causing cardiomyopathy. Bone marrow dysfunction manifesting as neutropenia and anemia is a common hematological finding. Although rare, three cases of secondary hemophagocytosis were documented.

CASE PRESENTATION

An 18-year-old male patient diagnosed with methylmalonic acidemia presented with vomiting and altered mental status. He had a medical history of presumably hemophagocytic lymphohistiocytosis (HLH) at the age of 17 months. Physical examination, laboratory tests, and bone marrow aspiration results met the HLH-2004 diagnostic criteria, confirming a recurrent HLH. Although he recovered after intensive treatment, his cognitive function declined. Retrospective analysis revealed higher serum levels of ferritin during acute decompensations compared with nonattack periods. Correlation analysis revealed a strong relationship between serum ferritin and propionylcarnitine, one of the major propionyl-CoA-derived metabolites.

CONCLUSIONS

HLH is a rare and underrecognized hematologic emergency in methylmalonic acidemia, and its early diagnosis and treatment are critical. Serum ferritin may be a useful clinical biomarker in the diagnosis of HLH-associated attacks in methylmalonic acidemia.

© 2025. The Author(s).

Address: Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan.; Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan. [email protected].; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. [email protected].; Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan.; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.; Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan.; Department of Pediatrics, Faculty of Medicine, University of Miyazaki Hospital, Miyazaki, Japan.; Department of Intensive Care, Fukuoka Children's Hospital, Fukuoka, Japan.; Division of Pediatrics, National Hospital Organization Fukuokahigashi Medical Center, Fukuoka, Japan.; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.; Center for Medical Genetics, Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.; Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.